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In October 2000, two hexavalent vaccines (Hexavac, Sa-
nofi Pasteur MSD and Infanrix Hexa, GlaxoSmith Kline) 
were licensed in the European Union for vaccinating chil-
dren against diphtheria, tetanus, pertussis, poliomyelitis, 
hepatitis B, and invasive infections caused by Haemo-
philus influenzae b. In September 2005, Hexavac was 
suspended by the European Medicines Agency (EMA) 
because of concerns over its ability to provide long-term 
protection against hepatitis B [1]. No action was taken 
over Infanrix Hexa since immunogenicity of its hepatitis 
B component did not raise equal concern. Until its sus-
pension in 2005, approximately 10 million doses of Hexa-
vac were distributed globally. Yet it is not known whether 
infants vaccinated with Hexavac have maintained protec-
tion or will require a booster vaccination to sustain immu-
nity. This issue is crucial in Europe – especially in Italy, 
Germany, Austria and at lesser extend in France, Greece 
and Spain – where Hexavac was given to several cohorts 
of infants from 2000 until suspension in 2005.
An open-label, randomised, controlled, multicentre 
study was carried out in Italy in order to assess the du-
ration of immunity from vaccination with Hexavac and 
Infanrix Hexa by testing whether concentrations of an-
tibodies against hepatitis B (anti-HBs) were retained in 
1543 children who had been vaccinated 5 years previ-
ously (833 with Hexavac and 710 with Infanrix Hexa), 
and whether a booster vaccination was needed [2].
At the start of the study, blood samples were taken from 
each child to measure levels of anti-HBs antibodies. 
Children with anti-HBs concentrations of 10 mIU/mL 
or higher were deemed immune. Children with levels of 
antibodies less than 10 mIU/mL were randomly assigned 
to a booster monovalent hepatitis B vaccine (either 5 μg 
of HBVaxPro, Sanofi Pasteur MSD or 10 μg of Engerix 
B, GlaxoSmithKline) and tested 2 weeks later.
Five years after primary immunisation, 38.4% of children 
who received Hexavac had protective concentrations of 
antibodies (≥ 10 mIU/mL) compared with 83.2% of chil-
dren who received Infanrix Hexa (p < 0.0001). Geometric 
mean concentration (GMC) was lower among children 
primed with Hexavac than among those primed with In-
fanrix Hexa (p < 0.0001). In the multivariate analysis the 
type of hexavalent vaccine given was the only determi-
nant of anti-HBs concentration after adjustment.
However, children in both groups who received a boost-
er hepatitis B vaccination had a similar rapid anamnestic 
response, and the proportion of children who responded 
to the booster were similar between groups. 92.1% of 
children originally given Hexavac and 94.3% of children 
originally given Infanrix Hexa showed protective levels 
of antibodies after the booster vaccination, thus showing 
the presence of specific immune memory.
Side-effects were infrequent, mild, and did not differ be-
tween the two booster groups. No serious adverse events 
were reported.
These results suggest that infant immune systems are 
able to recall responding to hepatitis B more than 5 
years after primary immunisation with hexavalent vac-
cines, thereby providing effective protection even in 
children showing low (< 10 mIU/ml) or undetectable 
levels of antibodies. Together, these findings suggest 
that in healthy children the immunological memory 
for hepatitis B surface antigen (HBsAg) may outlast 
the presence of antibody. In other words, children who 
have lost preventive antibody concentrations might still 
maintain T-cell memory that is able to trigger anti-HBs 
production by B cells when activated by revaccination 
or by natural exposure to hepatitis B virus (HBV) [3]. 
Therefore we can infer that if a vaccinated child is ex-
posed to HBV, the immune memory rapidly induces 
a vigorous anamnestic response which prevent against 
acute disease and the development of a chronic carrier 
state.
In conclusion, the main message from this study is 
that Hexavac, although somewhat less immunogenic 
that Infanrix Hexa, induced immune memory. Thus at 
present routine booster doses of hepatitis B vaccine do 
not seem necessary to sustain immunity in children vac-
cinated with hexavalent vaccines. Whether the memory 
persists for life is questionable, and evidence suggests 
that its persistence is associated with time after primary 
vaccination and likely to the strength of the initial im-
mune response [4, 5]. Additional follow-up is required 
to identify whether immunological memory persists 
during adolescence and adulthood – when risk of HBV 
exposure does significantly increase – or whether a 
booster might be needed later in life to maintain life-
long protection.
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